secwatch.observer — SEC 8-K summary
======================================

Issuer:     enVVeno Medical Corp (NVNO)
CIK:        0001661053
Form:       8-K
Filed at:   2026-04-29T23:59:59+00:00
Accession:  0001493152-26-019485
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 2.02, 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

enVVeno receives FDA IDE approval for pivotal study of non-surgical venous valve; $25M cash
--------------------------------------------------------------------------------

- FDA grants first-ever IDE for a U.S. pivotal study of a non-surgical replacement venous valve (enVVe System).
- TAVVE study: stage 1 enrolls 10 patients; stage 2 enrolls 220 patients (165 valve, 55 control) at up to 40 US sites.
- Company reports ~$25M cash/investments as of March 31, 2026, funding operations into Q3 2027.
- Addresses ~3 million U.S. patients with severe deep CVI; no effective current treatments for valvular incompetence.
- enVVe features: 13Fr delivery profile, porcine pericardium leaflet, no general anesthesia needed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661053/000149315226019485/0001493152-26-019485-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661053/000149315226019485/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-019485

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer